Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer
Authors:
Open Access
- 30 December 2024
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-13
Abstract
Immune checkpoint inhibitors (ICIs), including those targeting PD-1, are currently used in a wide range of tumors, but only 20–40% of patients achieve clinical benefit. The objective of our study was to find predictive peripheral blood-based biomarkers for ICI treatment. In 41 patients with advanced malignant melanoma (MM) and NSCLC treated with PD-1 inhibitors, we analyzed peripheral blood-based immune subsets by flow cytometry before treatment initialization and the second therapy dose. Specifically, we assessed basic blood differential count, overall T cells and their subgroups, B cells, and myeloid-derived suppressor cells (MDSC). In detail, CD4 + and CD8 + T cells were assessed according to their subtypes, such as central memory T cells (TCM), effector memory T cells (TEM), and naïve T cells (TN). Furthermore, we also evaluated the predictive value of CD28 and ICOS/CD278 co-expression on T cells. Patients who achieved disease control on ICIs had a significantly lower baseline proportion of CD4 + TEM (p = 0.013) and tended to have a higher baseline proportion of CD4 + TCM (p = 0.059). ICI therapy-induced increase in Treg count (p = 0.012) and the proportion of CD4 + TN (p = 0.008) and CD28 + ICOS- T cells (p = 0.012) was associated with disease control. Patients with a high baseline proportion of CD4 + TCM and a low baseline proportion of CD4 + TEM showed significantly longer PFS (p = 0.011, HR 2.6 and p ˂ 0.001, HR 0.23, respectively) and longer OS (p = 0.002, HR 3.75 and p ˂ 0.001, HR 0.15, respectively). Before the second dose, the high proportion of CD28 + ICOS- T cells after ICI therapy initiation was significantly associated with prolonged PFS (p = 0.017, HR 2.51) and OS (p = 0.030, HR 2.69). Also, a high Treg count after 2 weeks of ICI treatment was associated with significantly prolonged PFS (p = 0.016, HR 2.33). In summary, our findings suggest that CD4 + TEM and TCM baselines and an early increase in the Treg count induced by PD-1 inhibitors and the proportion of CD28 + ICOS- T cells may be useful in predicting the response in NSCLC and MM patients.Keywords
Funding Information
- Development of Research Organization MMCI (00209805)
- National Institute for Cancer Research (LX22NPO5102)
- Ministry of Health of the Czech Republic (NU21-03-00539)
- European Union—Next Generation EU and by Specific University Research (MUNI/A/1580/2023)
This publication has 41 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- CD4+T Cells: Differentiation and FunctionsJournal of Immunology Research, 2012
- CD8+ T Cells: Foot Soldiers of the Immune SystemImmunity, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapyInternational Journal of Cancer, 2010
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences, 2008
- Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving targetImmunology, 2008
- T cells and viral persistence: lessons from diverse infectionsNature Immunology, 2005
- ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 EngagementThe Journal of Immunology, 2001
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999